Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dalvance Protocol Accord With FDA + Actavis Marketing = Home Run?

This article was originally published in The Pink Sheet Daily

Executive Summary

With a Special Protocol Agreement and an experienced sales team lined up, all the firm has to do now is get hospitals excited about an expensive antibiotic in a highly-genericized market.

You may also be interested in...



Actavis Buys Durata In Bolt-On Deal, Leaves Room For Transformation

Actavis snaps up Durata for less than $1 billion, with significant contingent value tied to success of antibiotic Dalvance; meanwhile Actavis will likely continuing pursuing M&A.

Dalvance: First QIDP Antibiotic Breaks New Regulatory Ground; Label Doesn’t

Durata has post-marketing requirements to continue resistance-related studies, but its label includes stewardship language similar to other antibiotics.

Dalvance Approval Is Durata’s GAIN: First Test Of FDA’s Antibiotics Incentives

Durata has honor of having first drug approved under Qualified Infectious Disease Product designation and gains the benefits of an added five years of market exclusivity.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS076596

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel